Aysegul Ilhan-Mutlu - Publications

UCCL-IKF-AIO-STO-0124 NeoART-an international phase Ib/II platform trial investigating trastuzumab deruxtecan (T-DXd) combined with neoadjuvant chemotherapy for HER2-positive, resectable esophagogastric adenocarcinoma (EGA).

Journal: ESMO gastrointestinal oncology

Published: April 30, 2026

Cause-Specific Mortality in Gastroesophageal Cancer: A 30-Year Real-World Analysis from the Vienna Gastroesophageal Cancer Database.

Journal: Clinical epidemiology

Published: April 27, 2026

Therapeutic management of resectable mismatch-repair deficient/microsatellite instability-high gastroesophageal adenocarcinoma: a real-world analysis from Austria.

Journal: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association

Published: April 06, 2026

Lymphovascular Invasion (LVI) Correlates with Systemic Immune-Inflammation Index (SII) in Adenocarcinoma of the Gastroesophageal Junction (AEG): Implications for Prognostic Stratification.

Journal: Cancers

Published: June 23, 2025

Lack of association between prior or concurrent malignancies and overall survival in gastroesophageal cancer: evidence from a large European single-center cohort.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: May 19, 2025

Trastuzumab in Addition to Chemotherapy in Patients With Metastatic Human Epidermal Growth Factor Receptor 2-Positive Gastroesophageal Cancer-A Real-World Experience.

Journal: Clinical oncology (Royal College of Radiologists (Great Britain))

Published: April 29, 2025

Current Landscape of Molecular Biomarkers in Gastroesophageal Tumors and Potential Strategies for Co-Expression Patterns.

Journal: Cancers

Published: December 13, 2024

Correction to: Association of family history with patient characteristics and prognosis in a large European gastroesophageal cancer cohort.

Journal: Wiener klinische Wochenschrift

Published: October 18, 2024

Optimal timing for initiating first-line palliative systemic therapy in asymptomatic metastatic esophagogastric cancer: Insights from a European Delphi study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 03, 2024

Overexpression of Fibroblast Growth Factor 8 Is a Predictor of Impaired Survival in Esophageal Squamous Cell Carcinoma and Correlates with ALK/EML4 Alteration.

Journal: Cancers

Published: September 01, 2024

Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases.

Journal: Neuro-oncology

Published: July 04, 2024

Association of family history with patient characteristics and prognosis in a large European gastroesophageal cancer cohort.

Journal: Wiener klinische Wochenschrift

Published: June 04, 2024